Laboratory experiments in human and mouse brain organoids ... is mild and exclusively confined to the lungs, it can still provoke inflammation in the brain and impair brain cells’ ability to ...
Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...
Myant also acquired the technologies of Swiss deep tech company Osmotex, following a joint venture phase. The technologies enable precise control of moisture and particles in single microchannels, as ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the Committee for Medicinal Products for Human ...
The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...